Department of Pharmacology and Toxicology, National institute of Pharmaceutical Education and Research, Raebareli, Transit campus, Bijnour-sisendi road, Sarojini nagar, Lucknow 226002, Uttar Pradesh, India.
Department of Pharmacology and Toxicology, National institute of Pharmaceutical Education and Research, Raebareli, Transit campus, Bijnour-sisendi road, Sarojini nagar, Lucknow 226002, Uttar Pradesh, India.
Prog Neuropsychopharmacol Biol Psychiatry. 2021 Mar 2;106:110112. doi: 10.1016/j.pnpbp.2020.110112. Epub 2020 Sep 16.
Alzheimer's disease (AD) is a complex multifactorial disease involving chronic neuroinflammation and neurodegeneration. It has been recently recognized that gut microbiota interacts with the brain, and it is termed as microbiota-gut-brain axis. Modulation of this axis has been recently reported to affect the pathogenesis of neurodegenerative diseases, such as AD. Gut microbiota has a pivotal role in regulating multiple neuro-chemical pathways through the highly interconnected gut-brain axis. Recent emerging evidences have highlighted that the intestinal microflora takes part in bidirectional communication between the gut and the brain. Due to this, the researchers have suggested that human gut microflora may even act as the "second brain" and may be responsible for neurodegenerative disorders like Alzheimer's disease. Dysbiosis of gut microbiota can induce increased intestinal permeability and systemic inflammation. This may lead to the development of AD pathologies and cognitive impairment via the neural, immune, endocrine, and metabolic pathways. Thus, the modulation of gut microbiota through personalized diet, oral bacteriotherapy may lead to alteration of gut microbiota their products including amyloid protein. It has been demonstrated that modulation of the gut microbiota induces beneficial effects on neuronal pathways consequently leading to delay the progression of Alzheimer's disease. Thus, this approach may provide a novel therapeutic option for treatment of AD.
阿尔茨海默病(AD)是一种复杂的多因素疾病,涉及慢性神经炎症和神经退行性变。最近人们认识到,肠道微生物群与大脑相互作用,被称为微生物群-肠道-大脑轴。最近的研究报道称,这种轴的调节可能会影响神经退行性疾病(如 AD)的发病机制。肠道微生物群通过高度相互关联的肠道-大脑轴在调节多种神经化学途径中起着关键作用。最近涌现的证据强调了肠道微生物在肠道和大脑之间的双向通信中发挥作用。因此,研究人员提出,人类肠道微生物群甚至可能充当“第二大脑”,并可能导致阿尔茨海默病等神经退行性疾病。肠道微生物群的失调会导致肠道通透性增加和全身炎症。这可能通过神经、免疫、内分泌和代谢途径导致 AD 病理和认知障碍的发展。因此,通过个性化饮食、口服细菌疗法来调节肠道微生物群及其产物(包括淀粉样蛋白)可能会改变肠道微生物群。已经证明,调节肠道微生物群会对神经元途径产生有益的影响,从而延缓阿尔茨海默病的进展。因此,这种方法可能为 AD 的治疗提供一种新的治疗选择。